MannKind Corporation (MNKD)
MNKD trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/899460/000119312526073516/0001193125-26-073516-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | MNKD on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2004 |
| SEC CIK | 0000899460 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $349.0M |
| Net income | $5.9M |
| Operating income | $38.8M |
| Net margin | 1.7% |
| Operating margin | 11.1% |
| Revenue growth | +22.2% |
| Cash | $74.9M |
| Total assets | $792.2M |
| P/E (computed) | 217.0× |
| P/S (computed) | 3.6× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $41.3M cash; operating cash flow -$16.6M a quarter. | Report 2026-09-30 |
| Shares outstanding | 321,640,118 (2026-10-23); 307,070,281 a year earlier; 269,574,654 three years earlier. | Cover page 2026-10-23 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, Los Angeles, California, United States | PCAOB Form AP 2026-03-09 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $259K, sold $3.3M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $101.9M | -$23.2M | -$34.5M | $41.3M | $319.4M | $413.4M | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $109.4M | -$19.0M | -$18.4M | $52.9M | $319.1M | $393.6M | 10-Q 2026-08-05 |
| Q1 2026 2026-03-31 | $90.2M | -$16.6M | -$5.4M | $52.8M | $318.7M | $360.8M | 10-Q 2026-05-06 |
| Q4 2025 2025-12-31 | $112.0M | -$15.9M | -$8.0M | $74.9M | $354.6M | $349.0M | 10-K 2026-02-26 |
| Q3 2025 2025-09-30 | $82.1M | $8.0M | $23.6M | $127.4M | $109.7M | $313.8M | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | $76.5M | $668K | $8.9M | $57.0M | $36.2M | $301.7M | 10-Q 2026-08-05 |
| Q1 2025 2025-03-31 | $78.4M | $13.2M | -$6.4M | $47.3M | $36.1M | $297.6M | 10-Q 2026-05-06 |
| Q4 2024 2024-12-31 | $76.8M | $7.4M | $22.6M | $46.3M | $36.1M | $285.5M | 10-K 2026-02-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B7 | 2026-08-21 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-05 |
| Latest proxy | DEFA14A | 2026-04-07 |
Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +5.9% |
| 1 month | +35.4% |
| 3 months | +10.7% |
| Year to date | -27.2% |
| 1 year | -18.5% |
| From 52-week high | -33.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| GHRS | GH Research PLC | $18.75 | -1.83% | $1.3B |
| MLYS | Mineralys Therapeutics Inc. | $14.53 | -5.22% | $1.3B |
| NKTR | Nektar Therapeutics | $36.44 | -2.23% | $1.2B |
| AMPH | Amphastar Pharmaceuticals Inc. | $29.17 | -0.68% | $1.2B |
| AAPG | Ascentage Pharma Group International American Depository Shares | $13.29 | -9.10% | $1.2B |
| INVA | Innoviva Inc. | $18.49 | -2.84% | $1.3B |
| SLN | Silence Therapeutics Plc American Depository Share | $19.80 | -0.15% | $1.2B |
| OCUL | Ocular Therapeutix Inc. | $6.01 | -3.22% | $1.3B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier